

ISABS 2024
ABOUT INVITED SPEAKERS



Prof. Zvia Agur, Ph.D., President of the Institute for Medical BioMathematics (IMBM) As the senior scientist and President of IMBM, she is responsible for the innovative aspects and the scientific soundness of developed scientific concepts and methodologies. She acquired the appropriate background and training experience for this role in more than four decades of scientific research in mathematical biomedicine and over twenty years of experience in leading technology development in the Healthcare domain. During these years she made major contributions to the theory of disease dynamics, chemotherapy optimization and vaccination policies. Her scientific work was published in ca. 150 peer-reviewed papers in mathematical, medical, biological, and interdisciplinary professional journals and

books, and successfully applied pre-clinically and clinically. Over the last twenty-five years, she initiated and led collaborative interdisciplinary projects with clinicians from leading medical centers in the United States, Europe, and Israel. She is the Founder and President of the Scientific Research Institute for Medical BioMathematics (IMBM). As Founder & Chairperson of a company pioneering the development of tools for individualization of cancer treatment (closed), she led innovative development and was initiator and co-author of 13 granted USA, European and international patents. She has also been Co-Founder & President of the Israeli Society of Theoretical and Mathematical Biology and Co-Founder & Member of the Board of Directors of the European Society of Mathematical and Theoretical Biology (ESMTB). A 2016 finalist for the EU Prize for Women Innovators and was elected to the rank of 2022 Fellow of the American Association for the Advancement of Science for "developing computational models of diseases and incorporating these into medical software devices to facilitate drug development and personalized patient treatment."



Julie Allickson, Ph.D., is the Michael S. and Mary Sue Shannon director of Mayo Clinic's Center for Regenerative Biotherapeutics and the Otto Bremer Trust director, Biomanufacturing and Product Development, Center for Regenerative Biotherapeutics and Associate Professor of Regenerative Medicine. Dr. Allickson is leading the next phase of development of the Center for Regenerative Biotherapeutics as it delivers on innovations that Cure, Connect and Transform patient care in alignment with Mayo Clinic's 2030 vision. She directs the enterprise-wide biomanufacturing strategy that aspires to introduce new regenerative therapeutics into the practice and establish Mayo Clinic as a category of one in regenerative medicine for rare and complex conditions. Dr. Allickson provides

strategic leadership for all center activities and operations across the Mayo Clinic Enterprise. The Center for Regenerative Biotherapeutics has over 25 clinical trials in cell & gene therapy underway. With more than 25 years of experience in clinical translation of cellular therapies and regenerative medicine products, Dr. Allickson has expertise in business management,

regulatory affairs, strategic planning, project management and team building. She has been in industry and academic healthcare facilities. She has served as an executive officer of a publicly traded company that builds services for cellular banking, including licensure of technology with international affiliates. Mayo Clinic, Center for Regenerative Biotherapeutics across the enterprise including Minnesota, Arizona, and Florida. We are building a team of industry experienced leaders to frame a successful structure for Biomanufacturing including cellular therapies, gene and viral therapies, and tissue engineering and bioprinting technology.



Elizabeth Rosado Balmayor is currently a University Professor for Experimental Orthopaedics and Trauma Surgery at the RWTH Aachen University Hospital (Germany). She is the head of research at the Department of Orthopaedic, Trauma, and Reconstructive Surgery, and the director of the research institute for Experimental Orthopaedics and Trauma Surgery. She was trained as a Chemist and earned an M.Sc. in Materials Science and Technology at the University of Havana (Cuba). She received a Marie Curie scholarship in the area of Biomaterials and completed her Ph.D. in 2009 with Prof. Rui Reis at the 3B's research group (Portugal). Elizabeth obtained her assistant professorship in Experimental Trauma Surgery from TUM (Germany) in 2017. Thereafter, she moved to the MERLN Institute for

Technology-Inspired Regenerative Medicine at the Maastricht University (the Netherlands) where she was the Principal Investigator of the research group "Molecular Transfer and Therapy" until early 2022. She is an associate researcher with Prof. Chris Evans at the Mayo Clinic (USA). She holds visiting professorships at the Peruvian University Cayetano Heredia and the UNESCO Biomaterials chair of the University of Havana. Her achievements have been recognized with awards and grants; she has secured over 4.5 million euros from competitive grants for her research. Prof. Dr. Balmayor focuses on mRNA therapeutics for musculoskeletal tissue and tissue interface healing. A powerful breakthrough in her research is the development of a chemically modified mRNA encoding BMP-2 as an alternative to traditional gene therapy for bone healing. She holds a patent on this discovery, and her research has been widely published. She has made unique contributions to mRNA therapeutics applied to tissue engineering and the regenerative medicine field.



Atta Behfar, Ph.D., is the Russ and Kathy Van Cleve Professor of Regenerative Medicine at Mayo Clinic. His clinical area of focus is heart transplant and hemodynamic mechanical support devices. His research focus has been in regenerative medicine for the last 25 years with emphasis on stem cell and exosome innovation, translation, and clinical trial application.




Zwi N. Berneman, M.D. Ph.D. FRCP is Emeritus Professor of Hematology at the University of Antwerp, Antwerp, Belgium and previously Head of the Division of Hematology at the Antwerp University Hospital. His basic and clinical research is focused on vaccination with immunogenic dendritic cells in cancer and with tolerogenic dendritic cells in multiple sclerosis; and on retargeting T-lymphocytes against cancer with T-cell receptors directed against the tumor-associated Wilms' tumor protein (WT1). The Laboratory of Experimental Hematology, which he previously led, has pioneered mRNA electroporation as a clinically safe gene transfer methodology and has applied it to the fields of dendritic

cells and T-lymphocytes. He has been conducting clinical trials with cultured dendritic cells electroporated with mRNA since 2005 and can thus be considered as an early pioneer of the use of mRNA in medicine. To make clinical dendritic cell vaccination possible, he established the Center for Cell Therapy and Regenerative Medicine (CCRG) of which he is the Medical Director, at the Antwerp University Hospital and for which he obtained a Good Manufacturing Practices (GMP) Certification and Production License from the (Belgian) Federal Agency for Medicines and Health Products. He is a Fellow of the Royal College of Physicians, London, UK. He is the author or co-author of more than 340 peer-reviewed publications and his ISI h-index is 58.




Dr. Kapil Bharti obtained his Ph.D. from J.W. Goethe University, Frankfurt, Germany, graduating summa cum laude. His Ph.D. work involved research in the areas of molecular chaperones and epigenetics. He did his postdoc at the National Institutes of Health, where he published numerous papers in the areas of transcription regulation, pigment cell biology, and developmental biology of the eye. His lab at the National Eye Institute recently received started the first U.S. phase I/IIa trial to test autologous iPSC-derived RPE patch in AMD patients. Currently, he is co-developing a dual RPE/photoreceptor cell therapy with Opsi Therapeutics. He has given several keynote lectures, won several awards

including the NIH Director's award, NEI Directors Dr. Karl Kupfer Visionary award, and Sayer Vision Research lecture at NEI, and over two dozen keynote/award lectures for his revolutionary work on developing ocular cell-therapies. He serves on the advisory board (pro bono) of several stem cell therapies-based companies and patient-advocacy groups. His current work as a Senior Investigator at NEI involves understanding mechanism of retinal degenerative diseases using induced pluripotent stem cell derived eye cells and tissues and developing cell-based and drug-based therapies for such diseases. He is also the Director of the NEI Intramural Research Program where he oversees 21 research labs and 6 core facilities.



Prof. Frederick R. Bieber is a member of the Faculty of Medicine at Harvard University. He serves as Senior Medical Geneticist in the Center for Advanced Molecular Diagnostics, providing diagnostic laboratory genetic testing to patients and their families served by the MassGeneral/Brigham Hospital network in Boston. He has directed the undergraduate genetics course at Harvard for the past 40 years. Bieber's academic work focuses on medical genetics and the laboratory and statistical aspects of DNA-based human identification, with a focus on kinship analysis in forensic and humanitarian applications and its attendant legal, ethical, and public policy implications. He has testified in scores of civil and criminal cases in state, federal, and

military courts in the U.S. and abroad. Professor Bieber was a member of the FBI DNA Advisory Board (DAB) and was appointed to the first-ever National Commission on Forensic Science during the Obama administration. As a commissioned officer in the U.S. Army Reserve, he served at the U.S. Army Criminal Investigation Laboratory (USACIL) and the Armed Forces DNA Identification Laboratory (AFDIL). Bieber currently serves on the Advisory Committee of the National DNA Databank of Canada, the DNA Subcommittee of the New York State Forensic Commission, and the U.S. Forensic Sciences Standards Board (FSSB).



Dr. Bruce Budowle received a PhD in Genetics in 1979 from Virginia Polytechnic Institute and State University. From 1979-1982, Dr. Budowle was a postdoctoral fellow at the University of Alabama at Birmingham. Working under a National Cancer Institute fellowship, he carried out research predominately on genetic risk factors for diseases such as insulin dependent diabetes mellitus, melanoma, and acute lymphocytic leukemia. From 1983-2009, Dr. Budowle worked at the FBI's Laboratory Division to carry out research, development, and validation of methods for forensic biological analyses. He has published more than 700 articles, made more than 800 presentations, and testified in well over 300 criminal cases in the areas of molecular biology,

population genetics, statistics, quality assurance, and forensic biology. In addition, he has authored or co-authored books on molecular biology techniques, electrophoresis, protein detection, forensic genetics, and microbial forensics. Dr. Budowle recently retired as Director of the Center for Human Identification and Regents Professor at the University of North Texas Health Science Center at Fort Worth, Texas where his efforts focused on the areas of human forensic identification, microbial forensics, and emerging infectious disease with substantial emphasis in genomics and next generation sequencing. He continues to research and work in the areas of forensic genomics and contributes to supporting humanitarian efforts via human identification. He currently is a visiting professor in the Department of Forensic Medicine at the University of Helsinki and an adjunct professor in the Forensic Science Institute at Radford University.



Prof. Jung Kyoon Choi's research has primarily focused on cancer genomics. More recently, he leveraged the power of data science and artificial intelligence (AI) in emerging fields such as cancer immunotherapy, cancer detection, and single-cell genomics. In the realm of cancer immunotherapy, he utilized machine learning and single-cell genomics data to develop novel methods for neoantigen-based cancer vaccines and CAR-T cell therapies. Additionally, prof. Choi developed AI algorithms to predict clinical responses to cancer immunotherapy and to analyze cell-free DNA for early detection of multiple cancers.



Dr. Henry Erlich's laboratory has been involved for over 40 years in the development and application of molecular genetic technology such as PCR and DNA-based HLA typing for the analysis of infectious diseases and autoimmune diseases. They have also focused on the development of diagnostic tests for monogenic disease, such as cystic fibrosis and the hemoglobinopathies, as well as the application of PCR in forensic genetics. His lab performed the first forensic DNA case in the US in 1986 (Penn. Vs. Pestinikas) and the first post-conviction review. They were also being applying HLA typing system to the analysis of type 1 diabetes, inflammatory bowel disease, and many other autoimmune diseases. They have pioneered the application of next generation sequencing (NGS) to the analysis of the highly polymorphic HLA class I and class II

genes as well as to the analysis of mitochondrial DNA for forensic analyses. They applied HLA NGS systems to the analysis of cell free DNA in plasma for detecting donor DNA in recipient plasma for early detection of graft rejection. Recently, they are using a probe capture/NGS strategy to analyze fetal DNA in the maternal plasma to develop a non-invasive prenatal test (NIPT) for the beta-hemoglobinopathies.



Prof. Christopher Evans, Ph.D., is the John and Posy Krehbiel Professor of Orthopedics and Professor in the Departments of PM&R and Molecular Medicine at the Mayo Clinic. Dr. Evans serves as director of the Rehabilitation Medicine Research Center and is also the Maurice Müller Professor of Orthopaedic Surgery Emeritus at Harvard Medical School. Dr. Evans earned his B.Sc. in genetics and microbiology and his Ph.D. in biochemistry at the University of Wales, U.K. He completed a postdoctoral fellowship in molecular biology at Free University of Brussels, Belgium. From there he took a junior faculty position in the Department of Orthopaedic Surgery at the University of Pittsburgh, working his way through the ranks to become the inaugural Henry Mankin Professor of Orthopaedic Surgery and Professor of Molecular

Genetics and Biochemistry. While at the University of Pittsburgh he earned a Master's in the History and Philosophy of Science. He was subsequently awarded a D.Sc. degree by the University of Wales and an honorary M.A. from Harvard University. Dr. Evans studies clinical problems involving bones and joints, with an emphasis on developing novel biological therapies that can be translated into early phase clinical trials. His research has two main areas of focus: arthritis and regenerative orthopaedics. He has developed a gene therapy for osteoarthritis that recently completed a Phase I human, clinical trial at Mayo Clinic and is now the subject of a Phase Ib trial. Research in regenerative orthopaedics focuses on the use of gene delivery to promote the healing of bone, cartilage, tendon, and the intervertebral disc. Dr. Evans is a Fellow of the Learned Society of Wales, the Royal Society of Chemistry and the Royal College of Pathologists; an honorary Fellow of Swansea University and an inaugural Fellow of International Orthopaedic Research and the Orthopaedic Research Society, where he served as President. He is an honorary member of the Croatian Orthopaedic Society.



Dr. Robert L. Ferris, M.D., Ph.D., is Hillman Professor of Oncology and Director at UPMC Hillman Cancer Center, Director, UPMC Hillman Cancer Center, and Hillman Professor of Oncology, and UPMC Senior Vice President for Oncology Programs, and Associate Senior Vice Chancellor for Cancer Research, University Pittsburgh School of Medicine. As a head and neck surgical oncologist and translational tumor immunologist, his lab performs neoadjuvant "window" trials developing novel immune-oncology agents, combinations and biomarkers. His group is uniquely positioned to investigate mechanisms of anti-tumor immunity in the tumor microenvironment (TME), as well as tumor cell escape. Dr. Ferris's NIH-funded laboratory is focused on reversal of

immune escape and immunotherapy using monoclonal antibodies and vaccines, leading to the first randomized phase II-III trials of head and cancer immunotherapy in the world. He was founding director of the Hillman Tumor Microenvironment Center. He is a Principal Investigator of the University of Pittsburgh Specialized Program of Research Excellence (SPORE) grant for translational head and neck research and a R01 grant focused on T cell receptor dynamics and immune phenotypes regulating response to immunotherapy.



Dr. Arezou Ghazani, Ph.D. is a faculty member at Harvard Medical School, and the Director of Clinical Genomics at Brigham Genomic Medicine at Brigham and Women's Hospital. She is a board-certified medical geneticist (ABMG) and clinical scientist with 10 years of experience in clinical genomics and precision oncology. She is well-versed in CLIA/CAP genetic testing regulations across academia and industry. Dr. Ghazani's leadership role in clinical genomics involves the development and implementation of novel programs, platforms, and methods for the clinical interpretation of the genome, and investigation of complex genome structures. Dr. Ghazani is the Founder and the Chair of the multi-institutional INT²GRATE

[Oncology Consortium and Director of several large-scale genome programs at Brigham and Women's Hospital, including CroSeq Genome Program. Dr. Ghazani's research activities are focused on using an integrated approach in the evaluation of somatic (tumor) and germline (constitutional) genomic data to aid interpretation of germline variants and assessment of their clinical utility in cancer. Her passion for bridging scientific advances with current clinical needs led to the development of INT²GRATE. Implemented in a multi-institutional cancer consortium, INT²GRATE incorporates tumor-derived signature profiles and clinical genetic information to identify clinically actionable germline alterations in cancer patients.



Dr. Massimiliano Gnecci is an Associate Professor of Cardiology at the University of Pavia (Italy). He is a faculty member of the PhD program in Translational Medicine and of the Fellowship Programs in Cardiology, Internal Medicine and Respiratory Diseases. Prof. Gnecci is also the Director of the "Translational Cardiology Centre" at the IRCCS San Matteo Hospital in Pavia, Italy. His research interests include discovering new cell and molecular therapies for cardiovascular disease. In particular, he studied for several years the mechanisms of action through which MSCs heal infarcted hearts and the results of his research demonstrated for the first time that MSC act mainly through paracrine actions mediated by their secretome. His discovery paved the way for a new field of research based on stem cell-

derived secretomes and microvesicles to treat tissue repair. In addition, Prof. Gnecci leads an iPSC-based program for precision medicine strategies and drug discovery. Prof. Gnecci also does clinical research on acute myocardial infarction, secondary prevention in post-AMI and cardiac sudden death. Prof. Gnecci is the Chair of the Cardiovascular Committee and the 2021-23 regional Vice President Europe of the International Society of Cell Therapy. Recently, he was elected Chair of the Working Group on Cardiac Regeneration (CARE) of the European Society of Cardiology.



Dr. Mateja Hajdinjak (Dr. rer. nat.) is a Croatian molecular biologist using ancient DNA to study human evolutionary history. She is currently a Max Planck Research Group Leader of the Hominin Palaeogenomics group (HOPE) at the Max Planck Institute for Evolutionary Anthropology (MPI EVA) in Leipzig, Germany. She completed her PhD at the MPI EVA under the supervision of Dr. Matthias Meyer and Prof. Dr. Svante Pääbo, recovering and analysing genome-wide data of some of the last Neandertals and some of the earliest modern humans in Eurasia. As a Marie Skłodowska Curie Individual Fellow she then went to the Ancient Genomics Laboratory of Dr. Pontus Skoglund at the Francis Crick Institute in London, United Kingdom, where she continued working on human evolutionary genomics and tracing origins of modern human ancestry using ancient DNA.



Dr. Robert J. Hariri, M.D., Ph.D. pioneered the use of stem cells to treat a range of life-threatening human diseases and continues today to make transformative contributions in the fields of immuno-oncology and cell therapeutics along with tissue engineering and functional regeneration. He is widely acknowledged for his discovery of pluripotent stem cells derived from the human placenta, and as a member of the team that discovered the physiological activities of tumor necrosis factor (TNF). He holds over 200 issued and pending patents for discoveries including placenta-derived stem cells, which Nature recognized as one of the ten most important patent estates in the field. He has authored over 200 published chapters, articles, and abstracts. Dr. Hariri was the founder and CEO of Anthrogenesis Corporation, and

after its acquisition by Celgene Corporation, served as CEO of Celgene Cellular Therapeutics which was spun-out in 2017 to form Celularity. Dr. Hariri also co-founded the genomic-based health intelligence company, Human Longevity, Inc. and serves on numerous public boards including Cryoport (NASDAQ:CYRX). Dr. Hariri is an Adjunct Professor of Neurosurgery and member of the Board of Fellows of the Weill Cornell Medical College and a former member of the board of visitors of the Columbia University School of Engineering and Applied Sciences, and the Science & Technology Council of the College of Physicians and Surgeons. He is the recipient of numerous awards for his scientific contributions including The Thomas Edison Award, The Pontifical Medal for Innovation and The Fred Epstein Lifetime Achievement Award in Neurosurgery. Dr. Hariri completed his undergraduate education at Columbia University School of Engineering and Applied Sciences and Columbia College. He received his M.D. and Ph.D. degrees from Cornell University, where he was the recipient of both the Julian R. Rachele Award and the Doctoral Dissertation Award. He was a surgical resident and fellow in neurosurgery at The New York Hospital- Cornell Medical Center and served as an Assistant Professor of Neurosurgery and Associate Research Professor of Surgery at Cornell University Medical College.



Mitchell Holland, Ph.D., is a Fellow in the American Academy of Forensic Sciences, has served as an associate professorial lecturer and adjunct faculty member at various colleges and universities. Dr. Holland has been on the Editorial Board of the *Journal of Forensic Sciences* and a member of the Advisory Board of the *International Journal of Legal Medicine*. Prior to being asked in early 2005 to help develop the Forensic Science Program at Penn State, Dr. Holland was the Senior Vice President of Operations and Laboratory Director of The Bode Technology Group. At Bode, Dr. Holland led the efforts to produce DNA profiles from victim remains recovered from Ground Zero (World Trade Centers) following the terrorist attacks of 9/11. His group is currently leveraging the power of massively parallel sequencing

(MPS) to measure rates of mtDNA heteroplasmy in different population groups; evaluate the transmission of heteroplasmic variants between maternal relatives and tissue types; assess the impact of damage on the interpretation of low-level heteroplasmic variants; and develop best practices for the application of MPS approaches in forensic casework. In addition, members of Dr. Holland's group are exploring ways to extract small fragments of DNA from highly degraded skeletal material for STR and SNP analysis on an MPS platform.



Dr. Tae Hyun Hwang, Ph.D., is a distinguished researcher in machine learning and AI applications in cancer therapy, holding the Florida Department of Health Cancer Chair at Mayo Clinic. With a focus on immuno-oncology cell therapy and precision oncology, he leverages advanced technologies to explore treatment resistance within tumor immune microenvironments. At Mayo Clinic, he leads innovative research integrating computational techniques with biological insights to enhance precision oncology care. His efforts include developing novel therapeutic targets and biomarkers for CAR T/NK cell therapy. Dr. Hwang's work is globally recognized, making significant impacts on cancer research and patient care.



Prof. John P.A. Ioannidis was born in New York City and raised in Athens, Greece. He was Valedictorian at Athens College; received the National Award of the Greek Mathematical Society; and received his MD (top rank of medical school class) from the National University of Athens. He also received DSc in biopathology from the same institution. Trained at Harvard and Tufts (internal medicine, infectious diseases), then held positions at NIH, Johns Hopkins, Tufts, Harvard, Imperial College, and University of Ioannina. Moved to Stanford in 2010, initially as Director/C.F. Rehnberg Chair/Director at Stanford Prevention Research Center, then diversified with appointments in 4 departments and membership in 8 centers/institutes at Stanford. He launched the PhD program in Epidemiology & Clinical Research and the MS program in Community Health & Prevention Research at Stanford, as well as the Meta-Research Innovation Center at Stanford (METRICS). He has served as President of the Society for Research Synthesis Methodology and of the Association of American Physicians, as editorial board member of many leading journals and as Editor-in-Chief of the *European Journal of Clinical Investigation*. He has been elected to many honorific academies around the world and has received five honorary doctoral degrees and many awards. He is the author of nine literary books, three of them shortlisted for best book of the year Anagnostis awards in Greece. His work aims to improve research methods and practices and to enhance approaches to integrating information and generating reliable evidence. Full CV available at <https://profiles.stanford.edu/john-ioannidis>



Prof. Manfred Kayser is a molecular biologist and geneticist with a broad interest in human variation. Since 2004, he is (full) Professor of Forensic Molecular Biology at Erasmus MC University Medical Center Rotterdam, where he chairs the Department of Genetic Identification. His scientific interest is in understanding human (epi)genetic and (epi)genomic variation and applying it to address forensic, anthropological, and medical questions. During the last 20 years, his ground-breaking fundamental and applied research has innovated the field of forensic genetics in several subfields such as forensic DNA phenotyping, forensic Y-chromosome analysis, forensic tissue identification, forensic time estimation and he additionally published on forensic epigenetics, forensic microbiome analysis, and forensic massively parallel sequencing. He published over 300 articles in peer-reviewed scientific journals. He is the most cited scientist worldwide in the field of forensic genetics and second most cited in forensic medicine 1960-2022. He received several research awards such as from the International Society for Forensic Genetics (ISFG). Since 2023, he is elected member of the European Molecular Biology Organisation (EMBO).



Dr. Saad J. Kenderian, M.B., Ch.B., is a consultant in the Division of Hematology and Bone Marrow Transplantation, Department of Internal Medicine, at Mayo Clinic in Rochester, Minnesota, with joint appointments in the Department of Immunology and Department of Molecular Medicine. Dr. Kenderian serves as director of the T-Cell Engineering Laboratory Program, a federally funded laboratory focused on immunotherapy. He co-leads the Cancer Immunology Immunotherapy program within the Mayo Clinic Comprehensive Cancer Center and leads the cellular therapy and gene and viral therapy domains within the Center for Regenerative Therapeutics. He holds the academic rank of assistant professor of immunology, medicine and oncology, Mayo Clinic College of Medicine and Science. Dr. Kenderian

earned his M.B., Ch.B. at the University of Baghdad School of Medicine in Baghdad, Iraq. He completed a residency in internal medicine at McLaren Regional Medical Center at Michigan State University, where he served as chief medical resident. He further completed a fellowship in hematology and medical oncology, serving as chief fellow, at Mayo Clinic School of Graduate Medical Education. He continued his training in immunotherapy and chimeric antigen receptor T-cell therapy as a Mayo Clinic Scholar at the University of Pennsylvania School of Medicine. Dr. Kenderian's research focuses on the development, application, and optimization of novel next generation engineered T-cell therapies for the treatment of cancer and non-cancer applications. He and his research colleagues hold more than 150 patent applications covering 30 technologies and have published more than 100 manuscripts. Dr. Kenderian has given presentations on his research both nationally and internationally and has authored numerous journal articles and abstracts. He also holds reviewer and editorial responsibilities for prominent scientific publications.



Prof. Toomas Kivisild graduated as a Biologist and received his PhD in Genetics, from University of Tartu, Estonia, in 2000. Since then he has worked as a postdoctoral research fellow in the School of Medicine, at Stanford University (2002-3), Estonian Biocentre (since 2003), as the Professor and Head of the Department of Evolutionary Biology, University of Tartu (2005-6), and as a Lecturer and Reader in Human Evolutionary Genetics in the Department of Archaeology and Anthropology at the University of Cambridge (2006-2018). From 2018 he is a professor in the Department of Human Genetics at KU Leuven. His research interests include human evolution and evolutionary population genetics in the broadest sense. His recent work has focused on questions relating population structure with evolutionary processes such as selection, drift, migrations and admixture.

He is a co-author of the 2nd edition of 'Human Evolutionary Genetics' textbook and has led and co-authored in more than 100 peer reviewed papers on human population genetics.



Prof. Guido Kroemer is currently Professor at the Faculty of Medicine of the University of Paris-Cité, Director of the research team "Metabolism, Cancer and Immunity" of the French Medical Research Council (INSERM), Director of the Metabolomics and Cell Biology platforms of the Gustave Roussy Comprehensive Cancer Center, and Hospital Practitioner at the Hôpital Européen George Pompidou, Paris, France. His work focuses on the pathophysiological implications of cell stress and death in the context of aging, cancer and inflammation. He discovered the ignition of regulated cell death pathways by mitochondrial membrane permeabilization, the cytoprotective and antiaging effects of macroautophagy, as well as the decisive role of immunogenic cell death in anticancer treatments. With over 1600

articles including 63 papers in the 'CNS' Journals Cell (13 papers), Nature (5), Nature Medicine (21), Science (18) and Science Translational Medicine (6) and an h-index of 290, he is worldwide most cited researcher in Biology and Biochemistry. Kroemer is the founding Editor-in-Chief of five journals: Cell Death & Disease, Cell Stress, OncoImmunology, Microbial Cell, and Molecular & Cellular Oncology. He is the Editor-in-Chief of Seminars in Immunology and a member of the Academia Europaea, Austrian Academy of Sciences, Chinese Academy of Engineering, European Academy of Cancer Sciences (EACS), European Academy of Sciences (EAS), European Academy of Sciences and Arts (EASA), European Molecular Biology Organization (EMBO), German Academy of Sciences (Leopoldina), Institut Universitaire de France (IUF) and Royal Spanish Academy of Sciences. He is the Founding President of the European Academy of Tumor Immunology (EATI). His contributions have been recognized with multiple awards including the most prestigious cancer research prizes from Belgium (Baillet-Latour Health Prize), France (Prix Duquesne, Prix Léopold Griffuel, Grand Prix Ruban Rose) and Switzerland (Brupbacher Prize), the European Union-sponsored Descartes Prize, and the most important Italian science prize (Lombardia & Ricerca Prize).



Prof. Gordan Lauc, Ph.D., is a Professor of Biochemistry and Molecular Biology at the University of Zagreb, Director of the National Centre of Scientific Excellence in Personalised Healthcare, Honorary professor at the Kings College London and member of the Johns Hopkins Society of Scholars. He graduated Molecular Biology in 1992 and got PhD in Biochemistry in 1995 at the University of Zagreb. In 2017 he initiated the launch of the Human Glycome project and is one of its two co-directors. His research team is pioneering high throughput glycomic analysis and the application of glycan biomarkers in the field of precision medicine. By combining glycomic data with extensive genetic, epigenetic, biochemical, and physiological data on over 200,000 individual they are trying to understand the role of glycans in normal physiology and disease. Professor Lauc co-authored over 300 research articles that are cited over 15,000 times in

Google Scholar. In 2007 he founded Genos, a biotech company that is currently global leader in high throughput glycomics. Research in Genos led to the development of the GlycanAge test of biological age.



Dr. Nathan LeBrasseur, P.T., Ph.D., is a Professor in the Department of Physical Medicine and Rehabilitation and has a joint appointment in the Department of Physiology and Biomedical Engineering at Mayo Clinic. Dr. LeBrasseur is the Director of the Robert and Arlene Kogod Center on Aging, the Co-Director of the Paul F. Glenn Center for Biology of Aging Research, and Scientific Director of the Office of Translation to Practice at Mayo Clinic. He is the recent chair of the NIH Cellular Mechanisms in Aging and Development Study Section. Dr. LeBrasseur's research team conducts translational "bench-to-bedside" research on strategies to improve physical function, metabolism, and resilience in the face of aging and disease. His latest work has centered on cellular senescence, a fundamental mechanism of aging,

and interventions to counter this process to extend health span. Dr. LeBrasseur has received the Glenn Award for Research in Biological Mechanisms of Aging, the Nathan W. Shock Award Lecture from the National Institute on Aging, and the Vincent Cristofalo Rising Star Award in Aging Research from the American Federation for Aging Research. He is a Fellow of the Gerontological Society of America.



Prof. Dr. Henry C. Lee is one of the world's foremost forensic scientists. Dr. Lee's work has made him a landmark in modern-day criminal investigations. He has been a prominent player in many of the most challenging cases of the last 50 years. Dr. Lee has worked with law enforcement agencies in helping to solve more than 8000 cases. In recent years, his travels have taken him to England, Bosnia, Canada, China, Brunei, Bermuda, Germany, Singapore, Thailand, Middle East, South America, and other locations around the world. Dr. Lee's testimony figured prominently in the O. J. Simpson, Jason Williams, Peterson, and Kennedy Smith Trials; and in convictions of the "Woodchipper" murderer as well as thousands of other murder cases. Dr. Lee has assisted local and state police in their investigations of other famous

crimes, such as the murder of Jon Benet Ramsey in Boulder, Colorado, the 1993 suicide of White House Counsel Vincent Foster, the death of Chandra Levy, the kidnapping of Elizabeth Smart, and the reinvestigation of the Kennedy assassination. He was a consultant for more than 800 law enforcement agencies. Dr. Lee is currently a Distinguished Emeritus Professor in Forensic Science, Vice President of Institute of Forensic Science and the director of Forensic Research and Training Center of University of New Haven. He was the Chief Emeritus for the Connecticut State Police during 2000-2010 and was the Commissioner of Public Safety for

the State of Connecticut during 1998 to 2000 and has served as the state's Chief Criminalist from 1978 to 2000. Dr. Lee was the driving force in establishing a modern state police communication system, Community based police services sex offender and DNA databank, major crime investigation concepts and advanced forensic science services in Connecticut. In 1975, Dr. Lee joined the University of New Haven, where he created the school's Forensic Sciences program. He has also taught as a professor at more than a dozen universities, law schools.



Dr. David G. Lott, M.D. holds the academic rank of Professor of Otolaryngology at Mayo Clinic College of Medicine and Science. He serves as the Chair of the Department of Otolaryngology – Head and Neck Surgery/Audiology at Mayo Clinic Arizona. His practice includes voice and swallowing restoration, laryngeal cancer, and laryngotracheal reconstruction. Dr. Lott received his M.D. degree at the University of Iowa Carver College of Medicine and completed a residency in Otolaryngology/Head and Neck Surgery at the Cleveland Clinic Head and Neck Institute. He received further fellowship training in Laryngeal Surgery and Professional Voice at Harvard Medical School/Massachusetts General Hospital. Dr. Lott is the Associate Director of the Mayo Clinic Center for Regenerative Biotherapeutics on the

Arizona Campus. He is faculty for both the Clinical & Translational Science and Regenerative Sciences tracks within the Mayo Clinic Graduate School of Biomedical Sciences. In addition, he is the Director of the Head and Neck Regenerative Medicine and Transplantation Program at Mayo Clinic. The primary goal of the NIH-funded lab is to establish safe and effective clinical translation of regenerative medicine technology. The lab is initiating a FDA-approved human clinical trial to evaluate the efficacy of the tissue-engineered technologies. Additionally, the efforts of this program have established the world's first UNOS-approved laryngeal transplantation human clinical trial. Dr. Lott has received many awards and honors, including the Transform the Practice Award, Mayo Clinic Teacher of the Year Award, and the Mayo Clinic Distinguished Clinician Award.



Dr. Jorge M Mallea, M.D. is a consultant in the Department of Critical Care Medicine and the Center for Regenerative Biotherapeutics at Mayo Clinic Florida. He holds a joint appointment in the Department of Transplantation. He serves as the medical director for Lung Bioengineering Jacksonville (LB-JAX) a joint project between Mayo Clinic and Lung Biothechnology (a subsidiary of United Therapeutics). He is the chair for the Center for Regenerative Biotherapeutics' equity, inclusion and diversity committee and the Director for CRB's Seminar Series. Dr. Mallea received his M.D. degree at the Universidad Nacional de San Agustín. He completed a residency in Internal Medicine at New York

Medical College in New York. He received further fellowship training in Pulmonary, Critical Care and Sleep Medicine at Saint Louis University, Missouri. He joined the lung transplant team at Mayo Clinic Florida in 2011. Dr. Mallea's research interests include lung repair and regeneration, and organ preservation. He is conducting a FDA-approved clinical trial to evaluate the safety of mesenchymal stem cells in patients with advanced Chronic Obstructive Pulmonary Disease. He has served as principal investigator in industry sponsored clinical trials involving endobronchial valves to treat emphysema and centralized ex vivo lung perfusion facilities. Dr. Mallea serves as the chair for the American Society of Transplant Recovery and Preservation Community of Practice. He is a fellow of the American College of Chest Physicians and the American Academy of Sleep Medicine.

Dr. Shai Meretzki received his B.S. degree in biology and chemical engineering, and his M.S. and Ph.D. degrees in biotechnology, all from Technion–Israel Institute of Technology. After a brief stint in teaching, he joined Israeli biotechnology companies in different leadership positions. Together with Prof. Avinoam Kaduri, Dr. Meretzki founded the Bonus BioGroup, a Haifa-based biotechnology company of which he has served as CEO. Bonus BioGroup has revolutionized bone healing by having developed a unique technology for manufacturing viable human bone grafts as the world's first facility of its kind. Among Dr. Meretzki's achievement is the Bonus BioGroup's breakthrough technology. Their laboratory-grown bones promise to transform bone healing, offering hope to patients worldwide. Dr. Meretzki also founded Pluristem, where he served as both CEO and CTO. Pluristem is a biotech company specializing in cell therapies and regenerative medicine. In addition, Dr. Meretzki held leadership positions at Biological Industries (BI), Polyol Biotech, and Polyheal Ltd. His expertise spans various facets of the life sciences industry.



Dr. Ir. Eskeatnaf Mulugeta is an assistant professor at Erasmus University Medical Center Rotterdam (Erasmus MC) in The Netherlands. He has a multidisciplinary educational background with a Bachelor's degree in Pharmacy, followed by three Master's degrees in Biotechnology, Bioinformatics, and Molecular Medicine. He performed his PhD research at Erasmus MC in the lab of Prof. Dr. Joost Gribnau, where he investigated the evolution of mammalian sex chromosomes (X&Y) during evolution and development. He then moved to the Institut Curie (Paris, France) for his postdoctoral research (with Prof. Edith Heard), focusing on cancer genomics and epigenomics, and also adapting Naked mole rats as model animals for aging and cancer research. After completing his postdoctoral research, he started his research group at

Erasmus MC in the Department of Cell Biology. Eskeatnaf's current research focus includes deciphering and understanding gene regulatory networks that orchestrate normal and diseased development, understanding the role of the non-coding genome, developing novel single-cell omics techniques and analysis methods, and understanding the molecular mechanisms of longevity and cancer resistance in Naked mole rats. Additionally, in collaboration with Prof. Dr. Manfred Kayser (Department of Genetic Identification, Erasmus MC), he adapts single-cell omics

techniques and analysis methods for forensic applications. Eskeatnaf is also a coordinator of the genetics and genomics course at a graduate school and a lecturer in computational biology.



Prof. Giuseppe Orlando, M.D., Ph.D., Marie Curie Fellow, is a surgeon scientist at the Wake Forest School of Medicine in Winston Salem, North Carolina, US. He specializes in the transplantation, bioengineering and regeneration of the kidney and endocrine pancreas at Atrium Health Wake Forest Baptist Medical Center and the Wake Forest Institute for Regenerative Medicine. He received his MD, general surgery and PhD degrees from the University of Rome, Italy, and specialized in abdominal organ transplantation, transplant immunology, regenerative medicine, and tissue engineering in Paris (France), Brussels (Belgium), Oxford (England) and Winston Salem. He is the President Elect and Chair of the Education Committee of the Cell Transplant and Regenerative Medicine Society (CTRMS), the Co-Chair

of the Regenerative Medicine Advisory Council of the American Society of Transplantation and the Editor in Chief of a the Regenerative and Transplant Medicine new book series published by Elsevier-Academic press. He chairs the AST-Tissue Engineering and Regenerative Medicine International Society (TERMIS)-International Society of Cell and Gene Therapy (ISCT) cosponsored webinar series. The overarching goal of his scholarly activity is to bring the fields of transplant and regenerative medicine together to join forces and build their mutual future. As of March 11th, 2024, his h-index is 56 and has 10,351 citations



Prof. Walther Parson, Ph.D., holds an associate professorship at the Institute of Legal Medicine, Medical University of Innsbruck, Austria and an adjunct professorship at the PennState University, PA, USA. Together with his colleagues he set up the Austrian National DNA Database Laboratory in 1997 in Innsbruck, where he currently supervises the High Through-put DNA Database Laboratory and the research group Forensic Genomics. His research focuses on various fields of genetics and genomics, including forensic, medical and population genetics and he entertains collaborations with other fields of research such as anthropology, archaeology, ethics, history and mathematics. His group was repeatedly assigned to handle international requests on Forensic DNA fingerprinting of victims of mass fatalities

(e.g., the 2004 Tsunami, the 1973 victims Chile, the 2014 Missing Mexican students), international human identification cases (e.g., the Russian Tsar family Romanov) and identification of individuals of historic interest (e.g., Friedrich von Schiller, Wolfgang Amadeus Mozart). WP is representing Austria in international boards including the European Network of Forensic Science

Institutes (ENFSI) DNA Working Group and the European DNA Profiling Group (EDNAP) and he is an elected active member of the National Academy of Sciences Leopoldina. He served as President of the International Society for Forensic Genetics (ISFG) from 2015-2019 and is currently Vice-President. He received the Scientific award of the German Society of Legal Medicine (DGRM) in 2004 and the Scientific award of the International Society for Forensic Genetics (ISFG) in 2005. WP has co-authored >480 peer-reviewed publications with an h-index of 90 (Google Scholar, Feb 2024).



Dragan Primorac, M.D., Ph.D., is a pediatrician, forensic expert and geneticist. He is the first recipient of the title "Global Penn State University Ambassador" and currently he serves as the Chair of the International Affairs Committee of the American Academy of Forensic Sciences. He is professor at Eberly College of Science, The Pennsylvania State University, and Henry C. Lee College of Criminal Justice and Forensic Sciences, University of New Haven, in the United States and as professor at Medical Schools in Split, Osijek and Rijeka as well as at Department of Biotechnology, University of Rijeka, in Croatia. In October of 2016, he was appointed as a visiting professor at the College of Medicine and Forensics, Xi'an Jiaotong University, People's Republic of China. Dr. Primorac is one of the pioneers in

DNA identification of skeletal human remains from mass graves. Currently, he has particular interest in metabolic bone and cartilage disorders, pain treatment, sports medicine as well as in personalized and regenerative medicine. Dr. Primorac was invited speaker at more than 150 conferences all around the world. His work was published in most cited journals including Science and Nature and his papers have been cited more than 4300 times (Google Scholar) while h-index is 29. Currently, he is a team leader of the Croatian partner in the international consortium within EU FP7 project entitled "Multi-dimensional OMICS approach to stratification of patients with low back pain", worth 7.6 million euros. He is the cofounder and the President of the International Society of Applied Biological Sciences (www.isabs.hr). In 2017, he was elected president of The Croatian Society for Human Genetics. Dr. Primorac received 21 domestic and international awards. From 2003 to 2009 he served as Minister of Science, Education and Sports of the Republic of Croatia.



Prof. Antti Sajantila, M.D., Ph.D., works as a professor of forensic medicine in the Department of Forensic Medicine, at the University of Helsinki, and as a senior medical examiner in the Forensic Medicine Unit at the Finnish Institute of Health and Welfare. He is an Honorary Professor of Pontificia Universidad Católica del Perú in Lima. He received the ISFG Scientific Prize in 1997. Professor Sajantila is a member of the executive board of European Council of Legal Medicine and the Steering Committee of the Independent Forensic Expert Team hosted by the International Rehabilitation Council for Torture Victims. He has served in the Advisory Board for the United Nations Human Rights Special Rapporteur for the Minnesota Protocol on the Investigation of Potentially Unlawful Death. Professor Sajantila has participated in many

international medico-legal investigations, implemented on the requests of various international communities. Professor Sajantila has published over 230 articles in peer-reviewed scientific journals and co-authored books in forensic genetics, pathology, and pharmacogenetics. His current research interests are ancient DNA, archaeovirology, forensic genetics and forensic pathology.



Dr. Thomas Salinas, Ph.D., is Professor and Chair of Dental Specialties at the Mayo Clinic, where his time is dedicated to rehabilitation of patients with complex care needs. He has authored 95 publications related to prosthodontics and interdisciplinary care. His research interests are biomaterial behavior and clinical outcome studies. He is Board Certified in Prosthodontics and serves as an examiner for the American Board of Prosthodontics. He is a fellow of the American College of Prosthodontists, The Academy of Prosthodontics, and Past President of American Academy of Maxillofacial Prosthetics. A native of New Orleans, Louisiana he was educated at Louisiana State University Health Science Center and MD Anderson Cancer Center.



Dr. Nidhi Shah, M.D., is a pediatrician-medical geneticist and physician-scientist, with a research interest in implementation science, studying precision genomic medicine as well as novel applications of genetic tools and technologies. She completed fellowship training in clinical genetics at the Harvard Medical School Genetics Training Program. She serves as a Clinical Geneticist at Dartmouth Health Children's and Assistant Director of Center for Clinical Genomics and Advanced Technology (CGAT) in the Department of Pathology at Dartmouth Health and is part of the core scientific team working on the NIH funded Babyseq2

project. She is the Lead for Data and Analytics within the International Consortium of Newborn Sequencing (ICoNS).



Dr. Nikolaos Skartsis, M.D., Ph.D., is a transplant nephrologist, who is active in both clinical practice and research investigation. Dr. Skartsis is a physician/scientist with an overarching goal to promote the discovery of novel biologic drugs and cell therapies. His research focus is on the molecular pathways that lead to organ rejection and autoimmunity. Dr. Skartsis is an inventor of a novel method of ex-vivo Treg cell manufacturing that can be used in transplantation and autoimmune diseases. Dr. Skartsis has authored multiple scientific manuscripts and has given national and international invited lectures.



Dr. Doris Taylor, Ph.D., is CEO of Organamet Bio Inc. a biotech company committed to bioengineering personalized human hearts on demand. Taylor, a pioneer in cardiovascular regenerative medicine, led the first stem cell therapy in heart in the 1990s. She founded a company that went public in 2022 and was purchased by United Therapeutics in 2023. She is a fellow of the European Society of Cardiology, the American College of Cardiology, the American Heart Association and the American Institute of Biological and Medical Engineering. She is a senior member of the National Academy of Inventors.



Prof. Serena Tucci, Ph.D., is Assistant Professor of Anthropology, Ecology and Evolutionary Biology and Principal Investigator of the Human Evolutionary Genomics Laboratory at Yale University. Dr. Tucci's research addresses fundamental questions in human evolution and population history using DNA from present-day and ancient humans. Her interdisciplinary approach combines expertise from anthropology, population genetics, and computational biology, to reconstruct past demographic events and disentangle the genetic basis of human adaptation and disease. By integrating field work, laboratory work and cutting-edge computational methods, her work sheds light on mechanisms of evolutionary change, and on the genetic legacy that extinct humans - such as Neandertals and the enigmatic Denisovans - left in the genomes of

human wehlingpopulations in Island Southeast Asia and Oceania. Prior to joining Yale, she conducted postdoctoral research at the Department of Genome Sciences at the University of Washington and the Lewis-Sigler Institute for Integrative Genomics at Princeton University. She was awarded the Maximizing Investigators' Research Award by the National Institute of General Medical Sciences, and her work has been supported by the Lewis and Clark Fund for Exploration and Field Research from the American Philosophical Society. Tucci received her Ph.D. in Evolutionary and Environmental Biology from the University of Ferrara in Italy, where she was awarded the Young Investigator Fellowship in 2013 and 2015.



Prof. Dr. Ron H.N. van Schaik, Ph.D./FACB, is a European Specialist Laboratory Medicine and Full Professor Pharmacogenetics (2013) and of Clinical Chemistry (2023). He is head of the Dept. Clinical Chemistry at Erasmus MC - University Medical Center Rotterdam and Director of the International (IFCC) Expert-Center for Pharmacogenetics. Main interest is implementation of pharmacogenetics in clinical practice. He published >350 peer reviewed articles (h-index 81; Google Scholar). Specific research topics include pharmacogenetics in oncology, cardiology, psychiatry, and pain medication, as well as ctDNA/liquid biopsy analyses and genetics behind opioid use disorder. Prof. van Schaik participates in national (DPWG) and international groups on pharmacogenetics (ESPT, PGRN, CPIC, PharmVar, AMP, EMA) and is chair of the Dutch Network Clinical Pharmacogenetics. He is recipient of the Ortho Clinical Diagnostics Award for Outstanding Research (2001), the AACC Outstanding Speaker Award (2009) and the AACC/Mol Pathology Award for Outstanding Scientific Research (2010).



Dr. Samuel Volchenboum, Ph.D., is a professor of pediatrics and the associate chief research informatics officer for the Division of Biological Sciences at the University of Chicago. He is the Dean of Masters Programs, and he designed and launched the UChicago Master's in Biomedical Informatics. His clinical specialty is pediatric hematology / oncology, caring for kids with cancer and blood diseases. His research group includes the University of Chicago's Data for the Common Good (D4CG), dedicated to building communities, platforms, and ecosystems that maximize the potential of data to drive discovery and improve human health. D4CG's flagship project, the Pediatric Cancer Data Commons is dedicated to liberating and democratizing international data for pediatric malignancies. He is the director of the Informatics Core for the Clinical and Translational Science Award (CTSA), and he is director of the UChicago Clinical Informatics fellowship program.



Prof. Stanimir Vuk-Pavlović, Ph.D., is Professor Emeritus of Biochemistry and Molecular Biology at the Mayo Clinic College of Medicine and Science, as well as Director Emeritus of the Stem Cell Laboratory, Mayo Clinic Comprehensive Cancer Center in Rochester, Minnesota. He is a native of Zagreb where he graduated from the School of Science, University of Zagreb. He obtained his Ph.D. in biophysics from the same University and received his postdoctoral training at the Weizmann Institute of Science, Rehovot, Israel. After a stint at the Institute of Immunology in Zagreb, he joined the Mayo Clinic, where he has remained for the rest of his career. For his contribution to the Croatian war of independence, he was awarded two presidential medals.

Prof. Vuk-Pavlović is the corresponding (foreign) member of the Croatian Academy of Science and Arts. He has been involved with ISABS from the very beginning, joining Dragan Primorac and the late Moses Schanfield in organizing ISABS conferences. He initiated the collaboration of ISABS with the Mayo Clinic and has served as program director for several past conferences, including the current one.



Prof. Susan Walsh, Ph.D., received her BSc. in Biochemistry from University College Cork, Ireland, an MSc. in DNA profiling from the University of Central Lancashire, UK, and a Ph.D. in Forensic Genetics from Erasmus University in the Netherlands. She was a Research Assistant at the University of Sydney, Australia, and a Postdoctoral Research Associate in Anthropology at Yale University, CT, USA. She is now an Associate Professor of Biology at Indiana University Indianapolis (IUI), IN, USA, where her laboratory focuses on understanding the genetics of human physical appearance, from pigment to facial structure, and its prediction from DNA. She has published over 40 peer-reviewed articles in the last 10 years spanning the fields of genetics, forensics and bioinformatics. Her research has been funded by the US NIJ, DOD and NIH.



Prof. Peter Wehling, Ph.D., is a specialist for orthopedics, sports medicine and pain management from Düsseldorf, Germany. Dr. Wehling invented and established the Regenokine® Program. Together with a team of international experts, Dr. Wehling has significantly shaped the growing field of molecular orthopedics through pioneering that many orthopedic diseases are not merely wear and tear. Rather, they are linked to biomolecular changes, such as inflammation, oxidative stress and regenerative deficiency. Peter Wehling's expertise focuses on non-surgical, targeted approaches engaging the abilities of the patients' immune system. This way, the overarching goal is to restore natural balance and healthy conditions in diseased tissue in a sustainable as well as gentle manner.



Prof. Laurence Zitvogel, M.D. (Clinical Oncology), Ph.D. (Tumor Immunology), full professor at the University Paris Saclay, graduated in Medical Oncology in 1992. Scientific career first at the University of Pittsburgh, US. Became Research Director at Institut National de la Santé et Recherche Médicale U1015, and Scientific Director of the Clinicobiome program at Gustave Roussy, the largest cancer Center in Europe in 1998. Actively contributed to the field of cancer immunology and immunotherapy. Pioneer of the concepts of immunogenic cell death and gut microbiota in cancer immunosurveillance and therapies. Recipient of many awards: Translation Research INSERM Prize, the ASCO-SITC, Brupbacher Awards 2017, ESMO Immuno-Oncology Award 2017, Baillet Latour Prize 2019, the Griffuel

Prize 2019, the Duquesne Ligue Prize, and ITOC9 german award. Knighted Officer of Légion d'Honneur by French Ministry of Health 2019 and elected member of the National Academy of Medicine 2021. Her H-factor is 145, with >500 publications on PubMed, 108 265 citations in Clarivate analytics (highly cited researchers 2021, 2020, 2019, 2018, 2017, 2016).